Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

The safety and effectiveness of atezolizumab in PD-L1 advanced non-small cell lung cancer

Posted by on Aug 5, 2017 in Lung cancer | 0 comments

In a nutshell This trial looked at the effectiveness and safety of an immunotherapy drug, atezolizumab (Tecentriq). The authors concluded that this drug is effective and safe to treat patients with advanced non-small-cell lung cancer who have high levels of the PD-L1 protein. Some background Immunotherapy is a fairly new type of cancer treatment....

Read More

Recommendations on adjuvant therapy for patients with early stage non-small-cell lung cancer

Posted by on Aug 5, 2017 in Lung cancer | 0 comments

In a nutshell This article presents updated guidelines on treating non-small cell lung cancer patients with adjuvant (following surgery) chemotherapy or radiation. The authors provide recommendations on when to use adjuvant therapy based primarily on disease stage. Some background Cancer patients who have tumors removed by surgery often undergo...

Read More

Brigatinib for the treatment of previously treated ALK-positive non-small-cell lung cancer

Posted by on Aug 2, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined a new therapy, brigatinib (Alunbrig), in treating patients with ALK-positive non-small-cell lung cancer (NSCLC) that has progressed passed initial treatments. The authors concluded that brigatinib was safe and effective at treating this type of cancer. Some background One type of NSCLC is caused by genetic...

Read More

Long-term effects of stereotactic ablative radiotherapy for patients with NSCLC

Posted by on May 2, 2017 in Lung cancer | 0 comments

In a nutshell The authors examined the long-term effects of stereotactic ablative radiotherapy (SABR) in treating patients with stage 1 non-small-cell lung cancer (NSCLC). They concluded that SABR is both safe and effective in the long-term. Some background SABR is a type of radiation used to treat inoperable early stage NSCLC. Studies have shown...

Read More

Osimertinib is effective in pretreated non-small cell lung cancer with EGFR-T790M mutations

Posted by on May 1, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined the effectiveness and safety of osimertinib (Tagrisso) for treating patients with advanced non-small cell lung cancers that harbor T790M mutations. The authors concluded that the drug is promising in both safety and effectiveness at treating this type of cancer. Some background Non-small cell lung cancers...

Read More

Altering drug dosage during chemotherapy can decrease toxic side effects for patients with NSCLC

Posted by on Apr 15, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined whether altering the recommended dose of chemotherapy drugs during treatment was beneficial to patients. This trial concluded that altering doses of paclitaxel (Taxol) during chemotherapy could be beneficial to reduce neuropathy in patients with advanced non-small-cell lung cancer.      Some...

Read More

Surgery to treat stage 1 non-small cell lung cancer

Posted by on Apr 14, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined different surgical techniques to treat early stage non-small-stage lung cancer. The authors concluded that there was no difference in effectiveness between three different surgical techniques for patients with early stage NSCLC.   Some background Early-stage non-small cell lung cancer (NSCLC) is commonly...

Read More

Using aggressive treatment after first line treatment for advanced non-small-cell lung cancer

Posted by on Feb 20, 2017 in Lung cancer | 0 comments

In a nutshell The authors examined the use of local consolidative therapy to treat patients with advanced NSCLC with few metastases after first line treatment. They concluded that this is more effective than maintenance therapy alone for this specific group of patients. Some background Previous studies that examined treatment failure after first...

Read More